Table 1.
Cumulative percent inhibited MIC distribution of JNJ-Q2 and comparison with other fluoroquinolones tested against S. aureus subgroups
| Subgroup (no. of isolates tested) and antimicrobial agenta | No. (cumulative %) of isolates inhibited at indicated antimicrobial MIC (μg/ml) |
MIC50 (μg/ml) | MIC90 (μg/ml) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.008 | 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | >16 | |||
| All isolates (511) | |||||||||||||||
| JNJ-Q2 | 90 (17.6) | 12 (20.0) | 0 (20.0) | 0 (20.0) | 170 (53.2) | 161 (84.7) | 30 (90.6) | 34 (97.3) | 13 (99.8) | 1 (100.0) | 0.12 | 0.5 | |||
| Moxifloxacin | 27 (5.3) | 70 (19.0) | 5 (20.0) | 0 (20.0) | 0 (20.0) | 10 (21.9) | 179 (57.0) | 62 (69.1) | 94 (87.5) | 10 (89.4) | 54 (100.0) | 2 | >16 | ||
| Levofloxacin | 12 (2.3) | 86 (19.2) | 4 (20.0) | 0 (20.0) | 0 (20.0) | 120 (43.4) | 75 (58.1) | 53 (68.5) | 161 (100.0) | 8 | >16 | ||||
| Ciprofloxacin | 1 (0.2) | 22 (4.5) | 75 (19.2) | 4 (20.0) | 0 (20.0) | 0 (20.0) | 94 (38.4) | 88 (55.6) | 227 (100.0) | 16 | >16 | ||||
| FQR MRSA (308) | |||||||||||||||
| JNJ-Q2 | 127 (41.2) | 116 (78.9) | 24 (86.7) | 28 (95.8) | 12 (99.7) | 1 (100.0) | 0.25 | 1 | |||||||
| Moxifloxacin | 7 (2.3) | 131 (44.8) | 46 (59.7) | 69 (82.1) | 9 (85.1) | 46 (100.0) | 4 | >16 | |||||||
| Levofloxacin | 92 (29.9) | 51 (46.4) | 36 (58.1) | 129 (100.0) | 16 | >16 | |||||||||
| Ciprofloxacin | 74 (24.0) | 62 (44.2) | 172 (100.0) | >16 | >16 | ||||||||||
| FQR MSSA (101) | |||||||||||||||
| JNJ-Q2 | 43 (42.6) | 45 (87.1) | 6 (93.1) | 6 (99.0) | 1 (100.0) | 0.25 | 0.5 | ||||||||
| Moxifloxacin | 3 (3.0) | 48 (50.5) | 16 (66.3) | 25 (91.1) | 1 (92.1) | 8 (100.0) | 2 | 8 | |||||||
| Levofloxacin | 28 (27.7) | 24 (51.5) | 17 (68.3) | 32 (100.0) | 8 | >16 | |||||||||
| Ciprofloxacin | 20 (19.8) | 26 (45.5) | 55 (100.0) | >16 | >16 | ||||||||||
| FQS MRSA (50) | |||||||||||||||
| JNJ-Q2 | 49 (98.0) | 1 (100.0) | ≤0.008 | ≤0.008 | |||||||||||
| Moxifloxacin | 13 (26.0) | 36 (98.0) | 1 (100.0) | 0.06 | 0.06 | ||||||||||
| Levofloxacin | 2 (4.0) | 46 (96.0) | 2 (100.0) | 0.25 | 0.25 | ||||||||||
| Ciprofloxacin | 7 (14.0) | 41 (96.0) | 2 (100.0) | 0.5 | 0.5 | ||||||||||
| FQS MSSA (52) | |||||||||||||||
| JNJ-Q2 | 41 (78.9) | 11 (100.0) | ≤0.008 | 0.015 | |||||||||||
| Moxifloxacin | 14 (26.9) | 34 (92.3) | 4 (100.0) | 0.06 | 0.06 | ||||||||||
| Levofloxacin | 10 (19.2) | 40 (96.2) | 2 (100.0) | 0.25 | 0.25 | ||||||||||
| Ciprofloxacin | 1 (1.9) | 15 (30.8) | 34 (96.2) | 2 (100.0) | 0.5 | 0.5 | |||||||||
a
FQR, fluoroquinolone resistant; FQS, fluoroquinolone susceptible; MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus.